Company Overview and News
Blackham Resources Ltd (ASX:BLK) recently entered a memorandum of understanding (MoU) with Salt Lake Potash (ASX:SO4) to investigate a sulphate of potash opportunity.
Blackham Resources Ltd (ASX:BLK) has entered a memorandum of understanding (MoU) with Salt Lake Potash (ASX:SO4) to investigate a sulphate of potash opportunity.
Salt Lake Potash Limited ("SO4" or the "Company") announces that 42,000 ordinary shares of no par value ("Ordinary Shares") have been issued to an advisor in payment of part of their annual fee.
The Board of Salt Lake Potash Limited (the Company or SLP) is pleased to present its Quarterly Report for the period ending 30 June 2017. Highlights for the quarter and subsequently include:
A modest recovery in the mining and resources sector continued during the six month period to 31st March 2017. This improvement was reflected in our net asset value increasing from £1.16m as at 31 December 2016 to £1.24m as at 31 March 2017 and has continued to improve since period end; at the close of business on 16 June the value had increased to £1.67m or 3.34 pence per share on a discounted basis.
The Directors of Salt Lake Potash Limited advise that the following Appendix 3B and Section 708A Notice announcement has been released on the Australian Securities Exchange ("ASX"), as required under the listing rules of the ASX.
Salt Lake Potash Limited ("the Company") advises that it has today granted 1,000,000 performance rights to a key employee pursuant to the Salt Lake Potash Limited Performance Rights Plan, which was approved by shareholders at the Company's Annual General Meeting ("AGM") on 30 November 2016. The Performance Rights issued are subject to various performance conditions (including Pre-Feasibility Study, Definitive Feasibility Study, Project Construction and Production milestones) to be satisfied prior to the relevant expiry dates between 30 June 2018 and 30 June 2021.
Further to its announcement of 13 June 2017, Salt Lake Potash Limited (the "Company") announces that application has been made to the Australian Securities Exchange ("ASX") and the AIM market of the London Stock Exchange ("AIM") for a total of 10,300,000 new ordinary shares of no par value each ("Ordinary Shares"), which rank pari passu with the Company's existing issued Ordinary Shares, to be admitted to trading on both ASX and AIM.
The Board of Salt Lake Potash Limited (the Company or SLP) is pleased to provide an update on the Company's Goldfields Salt Lakes Project (GSLP), where work has accelerated substantially after the end of the summer wet season.
AIM and ASX listed Salt Lake Potash Limited ("the Company") advises that at the General Meeting of shareholders held earlier today, 13 June 2017, at 11.00am (WST), all resolutions were duly passed.
Salt Lake Potash Limited (the "Company") is pleased to announce the appointment of Mr Bryn Jones as a Non-Executive Director of the Company with immediate effect.
Salt Lake Potash Limited ("the Company") advises that it has today granted 200,000 performance rights to a key consultant pursuant to the Salt Lake Potash Limited Performance Rights Plan, which was approved by shareholders at the Company's Annual General Meeting ("AGM") on 30 November 2016. The Performance Rights, which entitle the recipient to acquire Salt Lake Potash ordinary shares at nil cost, are subject to various performance conditions (including Pre-Feasibility Study, Definitive Feasibility Study, Project Construction and Production milestones) to be satisfied prior to the relevant expiry dates between 30 June 2018 and 30 June 2021.
Salt Lake Potash Limited advises that with effect from 12 June 2017, the voluntary escrow period ceases for 15,000,000 ordinary shares and 22,500,000 performance shares.
Salt Lake Potash Limited ("the Company") wishes to advise that a General Meeting of the Company will be held at the Conference Room, Ground Floor, BGC Centre, 28 The Esplanade, Perth, Western Australia on Tuesday 13 June 2017 at 11:00am (WST).
Salt Lake Potash Limited (the "Company") announces that it has been notified, as a result of the share placement announced on 2 May 2017, of the following relevant changes to shareholdings in the Company:
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...